Drug
Ribavirin clinical trials
Also written Copegus, RBV, Rebetol and SCH 18908.
How each study uses Ribavirin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Ribavirin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Dec 1985 · VIRAZOLE · NDA 018859 (FDA, Drugs@FDA)
- European Union
- 6 May 1999 · Rebetol · EMEA/H/C/000246 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Other names
- RBV
- 34
In one entry with another drug
Given together, or one or the other
- Pegylated interferon alfa-2a and ribavirin
- 6
- Pegylated interferon and ribavirin
- 5
- Peginterferon alfa-2a and ribavirin
- 3
- Pegasys and Copegus
- 2
- PEGETRON combination therapy
- 2
- Combination of pegylated interferon alfa-2b and ribavirin
- 2
- pegylated interferon alpha 2a and ribavirin
- 2
- Pegylated Interferon alpha 2a + Ribavirin
- 2
Studies by the year they started
343 studies that test it; most in 2007 (30)
| Year | Studies |
|---|---|
| 1997 | 2 |
| 1998 | 2 |
| 1999 | 2 |
| 2000 | 3 |
| 2001 | 6 |
| 2002 | 12 |
| 2003 | 19 |
| 2004 | 20 |
| 2005 | 23 |
| 2006 | 19 |
| 2007 | 30 |
| 2008 | 10 |
| 2009 | 20 |
| 2010 | 14 |
| 2011 | 24 |
| 2012 | 28 |
| 2013 | 18 |
| 2014 | 24 |
| 2015 | 25 |
| 2016 | 20 |
| 2017 | 3 |
| 2018 | 4 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 171 · Other 187
Hoffmann-La Roche (31) · Merck Sharp & Dohme LLC (30) · National Institute of Allergy and Infectious Diseases (NIAID) (20) · Gilead Sciences (19) · AbbVie (17) · Vertex Pharmaceuticals Incorporated (11) · Bristol-Myers Squibb (8) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8)
Often tested with
Tested in the same studies.
Peginterferon alfa-2a (81) · Peginterferon alfa-2b (41) · Sofosbuvir (34) · Paritaprevir (20) · Telaprevir (20) · Dasabuvir (18) · Ombitasvir (18) · Interferons (18)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test Ribavirin, phase 3 first.
- Jun 2027ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyPhase 2/3 · Irrua Specialist Teaching Hospital
- Jan 2027Assessing Antiviral Treatments in Early Symptomatic RSVPhase 2 · University of Oxford
Studies
Open first, then newest update. How each study uses Ribavirin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 358
- ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyRecruitingPhase 2/3Irrua Specialist Teaching HospitalNCT06212336Written as Ribavirin
- Assessing Antiviral Treatments in Early Symptomatic RSVRecruitingPhase 2University of OxfordNCT06488300Written as Ribavirin
- UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHFRecruitingPhase 1/2Liverpool School of Tropical MedicineNCT05940545Written as Ribavirin
- Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic FeverSuspendedNot applicableU.S. Army Medical Research and Development CommandNCT02483260Written as Ribavirin
- Treatment of Hemorrhagic Fever With RibavirinSuspendedPhase 2U.S. Army Medical Research and Development CommandNCT04283513Written as Virazole
- Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02647632Written as Ribavirin
- Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected PatientsCompletedPhase 2University Hospital, BordeauxNCT00221650Written as Ribavirin
- Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver TransplantationCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT01463956Written as Ribavirin
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01466192Written as Ribavirin
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis CCompletedPhase 1Tanabe Pharma CorporationNCT00630058Written as MP-424(H), PEG-IFN-a-2b, RBV
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01468584Written as Ribavirin
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedPhase 3Tanabe Pharma CorporationNCT01753570Written as RBV(24 weeks)
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedPhase 3Anna CrucetaNCT01718301Written as Ribavirin
- Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAMCompletedPhase 2University Hospital, LimogesNCT00199719Written as Ribavirine
- Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer PatientsTerminatedPhase 1/2Jewish General HospitalNCT01309490Written as Ribavirin
- Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General HospitalCompletedPhase 4Nanogen Pharmaceutical Biotechnology Joint Stock CompanyNCT06922643Written as Ribavirin Oral Product
- Ribavirin for Hemorrhagic Fever With Renal SyndromeWithdrawnPhase 2U.S. Army Medical Research and Development CommandNCT00623168Written as Ribavirin
- The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue FeverCompletedPhase 3Khyber Medical University PeshawarNCT06744777Written as Ribavirin
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic ImpairmentCompletedPhase 1Boehringer IngelheimNCT02259855Written as Ribavirin
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedPhase 4M.D. Anderson Cancer CenterNCT05717400Written as Ribavirin
See all 358 studies that test Ribavirin →
Given beside what is tested · 295 — Ribavirin is usual care or a partner of the new treatment
- LAssa Fever Adjunct Treatment With DEXamethasoneRecruitingPhase 2Bernhard Nocht Institute for Tropical MedicineNCT06222723Written as Ribavirin
- Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe FibrosisCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT00148837Written as Peg-interferon alpha 2b + Ribavirin(drug)
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02107365Written as Ribavirin
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCCompletedPhase 3National Hepatology & Tropical Medicine Research InstituteNCT02771405Written as Ribavirin
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT01332955Written as Ribavirin
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00781274Written as Ribavirin
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT01753557Written as RBV
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT00780416Written as Ribavirin
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00780910Written as Ribavirin
- Pembrolizumab (MK-3475) in Hepatocellular CarcinomaCompletedPhase 2M.D. Anderson Cancer CenterNCT02940496Written as Ribavirin
- Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.WithdrawnPhase 3Fundacion Clinic per a la Recerca BiomédicaNCT02890719Written as Ribavirin 1200 mg/day
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CCompletedPhase 1/2HanAll BioPharma Co., Ltd.NCT01194037Written as Ribavirin
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01353911Written as Ribavirin
- Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)TerminatedPhase 2Merck Sharp & Dohme LLCNCT01440595Written as Ribavirin (RBV)
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02613403Written as Ribavirin
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive ParticipantsCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT01180790Written as Ribavirin
- Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV ParticipantsCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT01849562Written as Ribavirin
- Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT01700179Written as Ribavirin
- Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C InfectionCompletedPhase 2TaiGen Biotechnology Co., Ltd.NCT02340962Written as Ribavirin
- Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedPhase 3Bristol-Myers SquibbNCT01866930Written as Ribasphere (RBV)
Showing 20 of 295.
As the comparator · 22 — what is tested is compared with Ribavirin
- ARN-75039 Lassa Fever Treatment in West AfricaSuspendedPhase 2Arisan Therapeutics, Inc.NCT07419373Written as Intravenous ribavirin
- Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa FeverCompletedPhase 2Bernhard Nocht Institute for Tropical MedicineNCT04907682Written as Ribavirin iv
- Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 InfectionCompletedPhase 3PharmaEssentiaNCT04382937Written as P1101 + Ribavirin
- Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral ActivityStatus unknownPhase 3Ottawa Hospital Research InstituteNCT03759782Written as Ribavirin
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus InfectionCompletedPhase 3AbbVieNCT02723084Written as ribavirin (RBV)
- Effect of Recombinant Human Interferon α-2b Spray on HerpanginaCompletedPhase 4Children's Hospital of Fudan UniversityNCT03266601Written as Ribavirin
- Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth DiseaseCompletedPhase 4Children's Hospital of Fudan UniversityNCT02328651Written as Ribavirin
- A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedPhase 3Egyptian Liver HospitalNCT03186313Written as Sofosbuvir + Daclatasvir + Ribavirin
- Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedPhase 2/3Egyptian Liver HospitalNCT02483156Written as Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening
- The SIM-SOF Trial for Hepatitis CCompletedPhase 4Center For Hepatitis C, Atlanta, GANCT02168361Written as Ribavirin
- Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCVCompletedPhase 2Cairo UniversityNCT02690103Written as Ribavirin
- A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsCompletedPhase 3Bristol-Myers SquibbNCT01718145Written as Ribavirin
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis CCompletedPhase 2Beijing Kawin Technology Share-Holding Co., Ltd.NCT01908335Written as Pegasys /RBV
- Effectiveness Study of Integrative Treatment for Pediatric PneumoniaCompletedNot applicableLiaoning University of Traditional Chinese MedicineNCT02069665Written as Ribavirin Injection
- Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV PatientsCompletedPhase 2TransgeneNCT01055821Written as pegylated interferon and ribavirin
- A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian SubjectsCompletedPhase 3EMD SeronoNCT00249860Written as Ribavirin plus Interferon-beta-1a
- A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C InfectionWithdrawnPhase 3Boehringer IngelheimNCT01608737Written as PegIFN/RBV
- Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)CompletedPhase 2Bausch Health Americas, Inc.NCT00446134Written as Ribavirin
- Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHCCompletedPhase 4Brooke Army Medical CenterNCT00207363Written as Ribavirin, Peg interferon alfa 2b
- To Study the Efficacy and Safety of Renessans in Chronic HCV PatientsStatus unknownPhase 3MTI Medical Private Limited, PakistanNCT01463592Written as Interferon Alfa-2b AND RIBAVIRIN
Showing 20 of 22.
Codes
What other systems call Ribavirin · ClinicalTrials.gg INT008159
- MeSH (NLM) D012254RibavirinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 49717AWG6KRIBAVIRINConfirmed FDA, NLM, Wikidata
- RxNorm 9344Confirmed FDA, Wikidata
- Wikidata Q421862ribavirinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C807RibavirinOne source FDA
- DrugBank DB00811One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D012254 | Ribavirin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 49717AWG6K | RIBAVIRIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 9344 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421862 | ribavirin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C807 | Ribavirin | One source FDA |
| DrugBank | DB00811 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.